ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1596

Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors

Leslie R. Harrold1,2, George W. Reed1,2, Jennie Best3, Steve Zlotnick3, Gioia Persuitte2 and Joel M. Kremer4, 1University of Massachusetts Medical School, Worcester, MA, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4The Albany Medical College, Albany, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-TNF therapy, methotrexate (MTX), rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Clinical studies have demonstrated the superior efficacy of tocilizumab monotherapy (TCZ mono) to tumor necrosis factor inhibitor (TNFi) monotherapy and the comparable efficacy of TCZ mono with TCZ in combination with methotrexate (MTX). The objective of this study was to compare the effectiveness of TCZ mono vs TNFi in combination with ≤ 10 mg/week MTX (demonstrated effective dose with TNFi1) in patients with active rheumatoid arthritis (RA) and prior exposure to TNFis in routine clinical practice.

Methods: Eligible participants were TCZ-naive patients from the Corrona registry who had prior exposure to ≥ 1 TNFi, initiated TCZ mono or a TNFi + ≤ 10 mg MTX between 2010 and 2016 and had a 6-month follow-up visit. The primary outcome was mean change in Clinical Disease Activity Index (CDAI) from baseline at 6 months. Secondary outcomes included change in modified Health Assessment Questionnaire (mHAQ) score, achievement of low disease activity (LDA) or remission (CDAI ≤ 10) and achievement of modified American College of Rheumatology (mACR) 20/50/70 responses at 6 months. The main cohort was a trimmed population excluding patients who fell outside the propensity score (PS) distribution overlap. The PS included age, race, body mass index, smoking status, work status, disease duration, concomitant prednisone use/dose, prior biologic/TNFi use and a baseline disease assessment including ACR functional class, mHAQ, CDAI and patient pain. As a sensitivity analysis, a stratified-matched population was created (stratified by 1 vs ≥ 2 biologics, then matched on PS). Linear and logistic regression models were estimated in the trimmed population adjusting for the same covariates as in the PS.

Results: A total of 312 patients initiated TCZ mono and 119 initiated TNFi + ≤ 10 mg MTX (mean [SD] dose, 8.1 [2.6] mg). Using the PS, there were 416 patients in the trimmed population (TCZ mono, n = 304; TNFi + ≤ 10 mg MTX, n = 112). Both groups included middle-aged patients (mean age, TCZ mono, 59 years; TNFi + ≤ 10 mg MTX, 58 years) with established disease (mean disease duration, TCZ mono, 13 years; TNFi + ≤ 10 mg MTX, 12 years). Those initiating TCZ mono had more severe disease based on mean CDAI (28 vs 25; P = 0.029), mean reported pain (61 vs 55, P = 0.033) and prior use of ≥ 2 biologics (81% vs 58%; P < 0.001) compared with those initiating TNFi + ≤ 10 mg MTX. Both groups had improvement in CDAI and mHAQ and ≈ one-third of patients achieved LDA and a mACR20 response at 6 months. In adjusted models, improvement in disease activity was similar between the treatment groups (Table). Similar results were observed in the PS-matched cohort.

Conclusion: Treatment with TCZ mono or TNFi + ≤ 10 mg MTX in patients with prior TNFi exposure was associated with clinical improvement. TCZ mono appears to have similar efficacy as TNFi + MTX and warrants further study in a larger population. References:

1.    Burmester GR, et al. Ann Rheum Dis. 2015;74:1037-1044.


Disclosure: L. R. Harrold, Pfizer Inc, 2,Roche Pharmaceuticals, 5,Corrona, LLC, 3,Corrona, LLC, 1; G. W. Reed, Corrona, LLC, 3,Corrona, LLC, 1; J. Best, Genentech, Inc., 3; S. Zlotnick, Genentech, Inc., 3; G. Persuitte, Corrona, LLC, 3; J. M. Kremer, Corrona, LLC, 3,Corrona, LLC, 1,AbbVie, Amgen, BMS, Genentech, GSK, Lilly, Medimmune, Pfizer, and Sanofi, 5.

To cite this abstract in AMA style:

Harrold LR, Reed GW, Best J, Zlotnick S, Persuitte G, Kremer JM. Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/comparative-effectiveness-of-tocilizumab-monotherapy-with-tumor-necrosis-factor-inhibitors-in-combination-with-methotrexate-in-patients-with-rheumatoid-arthritis-and-prior-exposure-to-tumor-necrosis-f/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-effectiveness-of-tocilizumab-monotherapy-with-tumor-necrosis-factor-inhibitors-in-combination-with-methotrexate-in-patients-with-rheumatoid-arthritis-and-prior-exposure-to-tumor-necrosis-f/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.